🇺🇸 FDA
Patent

US 6998513

Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use

expired A61KA61K2039/505A61K49/0008

Quick answer

US patent 6998513 (Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use) held by The Regents of the University of California expires Mon Feb 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 14 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K49/0008